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esponsibility of InstAbstract The formulation of drugs is carried out with the principle objective of enhancing their
bioavailability. Poorly water soluble drugs are challenging for the formulation scientists with regard to
solubility and bioavailability. Lipid-based drug delivery systems (LBDDS) are one of the emerging
technologies designed to address such challenges. Encapsulating or solubilizing the drug in lipid
excipients can lead to increased solubilization and absorption, resulting in enhanced bioavailability.
Recent advances in these formulation technologies have led to the successful commercialization of lipid-
based formulations. This review provides a comprehensive summary and characterization of lipid-based
formulations, especially for oral delivery, from both physicochemical and biopharmaceutical perspectives.
This review also focuses on the processing techniques necessary to obtain solid lipid-based formulations
for oral delivery, along with a brief discussion of lipid excipients and their characterization.
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Figure 1 Schematic diagram of mechanisms of intestinal drug
transport from lipid-based formulations.
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Drawbacks to intravenous administration, including extravasation
of drug or blood, catheter infections, and thrombosis can be
prevented by administering the drug orally, making the oral
delivery the most popular route of administration1. Nonetheless,
oral administration is limited by problems related to physico-
chemical properties of the drug, including poor solubility, low
permeability, instability, and rapid metabolism, all of which
decrease oral bioavailability2.
With the advent of drug design, various molecules have been
created that have a potential for therapeutic action. But most of the
newly discovered chemical entities are of high molecular weight
and belong to biopharmaceutical classiﬁcation system (BCS) – II,
with poor aqueous solubility and high membrane permeability.
Hence these two characteristics limit the bioavailability of orally-
administered drugs3. These drugs have low solubility which leads
to low dissolution and limits absorption. This poor solubility not
only gives low oral bioavailability but also leads to high inter- and
intra-subject variability and lack of dose proportionality4. Also,
some of these drugs have enhanced bioavailability when co-
administered along with food, e.g., halofantrine5 and danazol6. In
order to formulate such drugs in a safe and efﬁcacious form, a
balance must be maintained between bioavailability, toxicity and
disposition within the body. Various techniques like microniza-
tion, complexation with cyclodextrins, solid dispersions, permea-
tion enhancers and surfactants have been reported to overcome
some solubility and permeability issues7.
In the last decade lipids have gained much interest as carriers
for the delivery of drugs with poor water solubility8. The
availability of novel lipid excipients with acceptable regulatory
and safety proﬁles coupled with their ability to enhance oral
bioavailability has helped in the development of lipid based
formulations as a means for drug delivery. Lipid-based
drug delivery (LBDD) systems have gained much importance in
the recent years due to their ability to improve the solubility and
bioavailability of drugs with poor water solubility9. The absorption
of drug from lipid based formulation depends on numerous
factors, including particle size, degree of emulsiﬁcation, rate of
dispersion and precipitation of drug upon dispersion4,10. Lipid-
based formulations may include oil solution or suspensions,
emulsions, self-micro or self-nano emulsifying drug delivery
systems (SMEDDS/SNEDDS)10,11. Some of the drugs that
are successfully marketed as lipid based formulations include
efavirenz (Sustivas), saquinavir (Fortovases), ritonavir (Nor-
virs), clofazamine (Lamprenes). An appropriate selection of
lipid vehicles, formulation strategies and rational delivery system
design can lead to the success of lipid based drug delivery
systems12.
A water-insoluble drug can be formulated as a lipid-based
formulation when the drug itself is an oil-like substance (e.g., ethyl
icosapentate, tocopherol nicotinate, teprenone, indomethacin far-
nesil and dronabinol), or when conventional formulation
approaches like granulation or soluble liquids in capsules do not
enhance the oral bioavailability13. A variety of lipid-based systems
composed of simple oil solutions to complex mixtures of oils, co-
solvents, surfactants and co-surfactants can be obtained based on
the type of excipients and formulation variables14. Indeed, these
systems can be converted to solid intermediates (powders, granules
and pellets) by various techniques and can be ﬁlled in hard gelatin
capsules or can be compressed into tablets after blending with
suitable tableting excipients9.2. Drug absorption
In practice, lipid formulations can be obtained as a result of
blending of excipients such as pure triglyceride oils, mixed
glycerides, lipophilic surfactants, hydrophilic surfactants and
water-soluble co-solvents10. These systems increase absorption
from the gastrointestinal tract by accelerating the dissolution
process, facilitating the formation of solubilized phases by reduc-
tion of particle size to the molecular level, yielding a solid-state
solution within the carrier4,15, changing drug uptake, efﬂux and
disposition by altering enterocyte-based transport16,17, and enhan-
cing drug transport to the systemic circulation via intestinal
lymphatic system18–20.
2.1. Lymphatic system
The lymphatic system plays an important role in the transport of
drugs to the systemic circulation, given its extensive drainage
network throughout the body. Some of the advantages of
lymphatic transport of drug are avoidance of ﬁrst-pass metabolism
and targeting of speciﬁc diseases which are known to spread via
lymphatics, such as certain lymphomas and HIV. Possible
mechanisms by which lipids affect drug absorption, bioavailability
and disposition after oral administration are summarized in
Fig. 121. The promising mechanisms include22: I facilitating
transcellular absorption due to increased membrane ﬂuidity; II,
allowing paracellular transport by opening tight junctions; III,
increased intracellular concentration and residence time by surfac-
tants due to inhibition of P-gp and/or CYP450; IV, lipid stimula-
tion of lipoprotein/chylomicron production15,18.
2.2. Digestion and solubilization
The balance between a drug's solubility in the aqueous environ-
ment of the gastrointestinal lumen and its permeation across
the lipophilic membrane of enterocytes determines its rate and
extent of absorption16. After oral administration of lipid-based
Figure 2 Lipid digestion and drug solubilization process in the small intestine.
Lipid-based drug delivery systems 363formulations, gastric lipase initiates the digestion of exogenous
dietary triglyceride (TG) and formulation TG. Simultaneously, the
mechanical mixing (propulsion, grinding and retropulsion) of the
stomach facilitates formation of a crude emulsion (comprised of
aqueous gastric ﬂuid and lipid digestion products). Later in the
small intestine, TG is broken down to diglyceride, monoglyceride
and fatty acids by pancreatic lipase together with its cofactor co-
lipase203, acting primarily at the sn-1 and sn-3 positions of TG to
produce 2-monoglyceride and free fatty acid23.
Pancreatic phospholipase A2 digests the formulation-derived or
biliary-derived phospholipids (PL) by hydrolyzing at the sn-2
position of PL to yield lysophosphatidylcholine and fatty acid24.
The presence of exogenous lipids in the small intestine stimulates
the secretion of endogenous biliary lipids from the gall bladder,
including bile salt (BS), PL and cholesterol. Previously formed
monoglycerides, fatty acids, and lysophospholipid (products of
lipid digestion) are subsequently incorporated into a series of
colloidal structures, including micelles and unilamellar and multi-
lamellar vesicles in the presence of bile salts. The solubilization
and absorptive capacity of the small intestine for lipid digestion
products and drugs (D) is signiﬁcantly enhanced due to these
formed lipid metabolites. In Fig. 2, the oil droplet in the intestine is
represented in different colors to indicate undigested TG in the
core (orange) and digested products such as fatty acid (blue) and
monoglyceride (green) on the surface of the droplet.2.3. The role of lipids in enhancement of bioavailability
The bioavailability of some of the drugs is increased when co-
administered with food3,20,25. However, many drug molecules
have negligible interaction with food. BCS class I drugs are not
affected by the presence or absence of food, but class II drugs have
an altered absorption when co-administered with food. The reason
for such enhanced bioavailability might be attributed to solubility,
permeability and inhibition of efﬂux transporters in the presence of
food26. Some of the drugs which show enhanced bioavailability
when administered along with food are griseofulvin27, halofan-
trine6, danazol5, troglitazone and atovaquone28. A guidance
document entitled “Food-Effect Bioavailability and Fed Bioequi-
valence” was issued by FDA in December 2002. The US FDA
recommended high fat meals for food-effect studies because such
fatty meals (800–1000 cal, 50%–65% fat, 25%–30%carbohydrates and 15%–20% proteins) affect GI physiology and
maximize drug transfer into the systemic circulation29.
In particular, it is the lipid component of the food that plays a
vital role in the absorption of lipophilic drugs,30 leading to
enhanced oral bioavailability. This can be explained by the ability
of a high fat meal to stimulate biliary and pancreatic secretions, to
decrease metabolism and efﬂux activity, to increase intestinal wall
permeability, and to a prolongation of gastrointestinal tract (GIT)
residence time and transport via lymphatic system31. Triglycerides
and long chain fatty acids play a major role in prolonging the GIT
residence time. Also, a high fat meal elevates the TG-rich
lipoproteins which react with drug molecules. This association
of lipoproteins with drug molecules enhances intestinal lymphatic
transport and leads to changes in drug disposition and ﬁnally
changes the kinetics of the pharmacological actions of poorly
soluble drugs32. This food effect on drug absorption leads to a
serious concern about the sub-therapeutic plasma drug concentra-
tion when co-administered without food. Such food effect is also a
serious problem for drugs with a narrow therapeutic index, where
increased bioavailability may lead to serious untoward effects.
Hence, control or/and monitoring of food intake is required when
dosing such drugs.
However, food-dependent bioavailability can be signiﬁcantly
reduced by formulating the drug as a lipid-based formulation,
which can increase the solubility and dissolution of lipophilic
drugs and facilitate the formation of solubilized species, from
which absorption occurs. Hence, lipid-based formulations can be
used to reduce the dose of drug while simultaneously enhancing its
oral bioavailability15.3. Lipid excipients
A wide range of lipid excipients are available from excipient
suppliers. Since these lipids affect the absorption process, it
is necessary to know the characteristics of various excipients14.
The factors that determine the choice of excipients for lipid-based
formulations include miscibility; solvent capacity; self-dispersibility
and ability to promote self-dispersion of the formulation; digest-
ibility and fate of digested products; regulatory issues – irritancy,
toxicity, purity, chemical stability; capsule compatibility; melting
point, and cost.
For preparing lipid-based formulations, dietary oils composed
of medium and long chain triglycerides, along with various
Table 1 Solubilizing excipients used in commercially available Lipid-based oral formulations36.
Water-insoluble excipients Triglycerides Surfactants
Bees wax, Long-chain triglycerides Polysorbate 20 (tween 20),
Oleic acid, Hydrogenated soyabean oil, Polysorbate 80 (tween 80),
Soy fatty acids, Hydrogenated vegetable oil, Sorbitanmonolaurate (Span20),
D-α-Tocopherol (vitamin E), Corn oil, Olive oil, D-α -Tocopheryl PEG 1000 succinate (TPGS),
Corn oil mono-di-triglycerides, Soyabean oil, Pea nut oil, Glycerylmonooleate,
Medium chain (C8/C10) mono and diglycerides, Sesame oil. Polyoxyl 35 castor oil (cremophor EL),
Propylene glycol esters of fatty acids. Medium-chain triglycerides Polyoxyl 40 hydrogenated castor oil (cremophor RH40),
Caprylic/capric Polyoxyl 60 hydrogenated castor oil (cremophor RH60),
triglycerides derived from PEG 300 oleic glycerides (Labraﬁls M-1944CS),
coconut oil or palm seed oil PEG 300 linoleic glycerides (Labraﬁls M-2125CS),
PEG 400 caprylic/capric Glycerides (Labrasols),
PEG 1500 lauric glycerides (Gelucires 44/14).
Table 2 Composition of fatty acids found in lipid-based
excipients36.
Fatty acid chain length
(number of carbons)
Common
name
Melting
temperature
(1C)
8 Caprylic acid 16.5
10 Capric acid 31.6
12 Lauric acid 44.8
14 Myristic acid 54.4
16 Palmitic acid 62.9
18 Stearic acid 70.1
18 Oleic acid 16.0
18 Linoleic acid 5.0
18 γ-Linoleic acid 11.0
18 Ricinoleic acid 6.0
20 Arachidic acid 76.1
22 Behenic acid 80.0
S. Kalepu et al.364solvents and surfactants are frequently chosen. Many lipids are
amphiphilic in nature, having a lipophilic portion (fatty acid) and a
hydrophilic portion33. The melting point increases as the fatty acid
chain length increases, but it decreases with the increase in the
unsaturation of the fatty acid and also increases the susceptibility
to oxidation9. A list of solubilizing agents used in lipid-based
formulations is mentioned in Table 1.3.1. Classiﬁcation of lipid excipients
3.1.1. Triglycerides
The most common excipients used in lipid based drug delivery are
triglyceride vegetable oils. This is one class of lipid which does
not present any safety issues, since they are fully digested and
absorbed14. Triglycerides can be further classiﬁed as long chain
triglycerides (LCT), medium chain triglycerides (MCT) and short
chain triglycerides (SCT). The capacity as a solvent for drugs is
mainly decided by the effective concentration of ester groups34.
MCT have a higher solvent capacity than LCT and are less prone
to oxidation35. Oils from different vegetable sources have different
proportions of each fatty acid. The composition of fatty acids36
found in various lipid excipients are presented in Table 2. D-α-
Tocopheryl polyethylene glycol 1000 succinate (Vitamin E TPGS)
is derived from vegetable tocopherols. It is water soluble and actsas absorption enhancer for poorly water-soluble drugs. Pure
triglycerides are presented in reﬁned vegetable oils37–39.
3.1.2. Mixed glycerides and polar oils
Mixed glycerides are obtained by partial hydrolysis of vegetable
oils. The starting material (triglyceride) and the extent of hydro-
lysis determine the chemical composition of the mixed glycerides
produced. Medium chain mixed glycerides are not susceptible to
oxidation, have greater solvent capacity and promote emulsiﬁca-
tion. These polar oily excipients also improve solvent capacity and
the dispersibility of the formulation. Sorbitan trioleate (Span 85) is
an example of polar oils. Apart from this, oleic acid is also used in
a number of commercial products40,41.
3.1.3. Cosolvents
In order to enhance the solubilization process, most marketed drug
products use cosolvents40,41. The popular cosolvents used include
ethanol, glycerol, propylene glycol and polyethylene glycols
(PEG)-400. The reason for their use can be attributed to an
increase in the solvent capacity of the formulation for drugs and to
aid the dispersion of systems which contain a high proportion of
water soluble surfactants. However, there are several practical
limits related to these cosolvents, including precipitation of the
solubilized drug from the solvent due to loss of the solvent
capacity following dilution42, immiscibility of some cosolvents
with oils, and incompatibilities of low molecular weight solvents
with capsule shells43.
3.1.4. Water-insoluble surfactants
A group of lipid excipients with intermediate hydrophilic-
lipophilic balance (HLB of 8–12) that adsorb at oil–water
interfaces are available. Depending on the degree of ethoxylation,
these have a ﬁnite solubility in water. They can form emulsions if
subjected to shear and are sometimes referred as being ‘disper-
sible’ in water. These substances can form micelles but are unable
to self-emulsify due to their insufﬁciently hydrophilic nature.
Oleate esters such as polyoxyethylene (20) sorbitan trioleate
(Tween-85) and polyoxyethylene (20) glyceryl trioleate (Tagot-
TO) are typical examples of water-insoluble surfactants whose
HLB values are between 11 and 11.5. However, a blend of Tween-
80 and Span-80 with average HLB value of 11 is not similar to
Tween-85 in function. The former consists of both water-soluble
and water-insoluble molecules, but the later consists of predomi-
nantly of water-insoluble molecules10,44,45.
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These are the most commonly used surfactants for the formulation
of self-emulsifying drug delivery systems8,46. The materials with
HLB value of approximately 12 or greater can form micellar
solutions at low concentrations by dissolving in pure water above
their critical micellar concentration47. These materials can be
synthesized by mixing polyethylene glycols (PEG) with hydro-
lyzed vegetable oils. Alternatively, alcohols can be made to react
with ethyleneoxide to produce alkyl ether ethoxylate, which is a
commonly used surfactant (e.g., cetostearyl alcohol ethoxylate
‘cetomacrogol’). A reaction of sorbitan esters with ethylene oxide
produces polysorbates (predominantly ether ethoxylates)48.
Cremophor RH40 and RH60 (ethoxylated hydrogenated castor
oil) are examples of this type which are obtained from hydro-
genation of materials derived from vegetable oils. Cremophor EL
(ethoxylated castor oil), which is not hydrogenated is also widely
used. Cremophor is known to enhance the absorption by inhibiting
the efﬂux pumps, but the mechanism of inhibition is not yet
determined37,49,50. This might be attributed to a non-speciﬁc
conformational change due to penetration of the surfactant
molecules into the membrane, adsorption on to the surface of
the efﬂux pumps, or interaction of molecules with intracellular
domains of efﬂux pump51,52.
3.1.6. Additives
In order to protect the formulation from oxidation, various lipid
soluble anti-oxidants such as α-tocopherol, β-carotene, propyl
gallate, butylated hydroxyl toluene (BHT) or butylated hydro-
xyanisole (BHA) can be used13.
3.2. Characterization of lipid systems
3.2.1. Physical analysis
Analysis of the thermal behavior of lipids during formulation is of
primary importance, since lipid excipients have complex chemical
compositions that lead to broad melting ranges. Various thermal
properties of lipids including crystallization temperature, melting
point, glass transition temperature and determination of solid fat
content of the excipient versus temperature can be evaluated using
differential scanning calorimetry (DSC). The organization of the
lipid during heating or cooling can be assessed by hot-stage
microscopy. Crystallinity of a lipid excipient can be conﬁrmed by
X-ray diffraction (XRD)9.
3.2.2. Chemical analysis
High performance liquid chromatography (HPLC) and gas chro-
matography (GC) can be used to determine the exact composition
of ethers, esters and fatty acid distribution. Other chemical indices
are also available: the molecular weight of fatty acids can be
determined from their saponiﬁcation value; the saturation of
hydrocarbon chains can be measured using an iodine-based assay;
oxidative changes can be determined by measuring peroxides; free
fatty acids can be measured from acid content; and free hydroxyl
groups can be determined by measuring hydroxyl group content9.
3.2.3. Dissolution in biorelevant media and dispersion testing
The FDA requires conventional USP dissolution testing as a
quality control tool for the formulations, but this dissolution does
not correlate to the in vivo behavior of lipid-based formulations. In
the GIT lipids are subjected to digestion processes in the presence
of gastric and pancreatic lipases19,53. These lipases also affect theemulsiﬁcation and dispersion properties of the lipid excipients,
leading to altered solubilization capacity in vivo. Hence, the
digestibility of the lipid excipients must be considered when
selecting lipid-based formulations10,54,55. To assess such effects
and predict in vivo behavior, dissolution testing in biorelevant
media can be helpful. The effectiveness of self-emulsifying
formulations can be determined by dispersion testing (emulsiﬁca-
tion capacity and particle size). Photon correlation spectroscopy
(PCS) or laser light diffraction can be used to measure the particle
size, and visual observation can be helpful to predict emulsiﬁca-
tion capacity56.
3.2.4. Analysis of physiological effects of excipients
Lipid-based excipients are known to enhance the oral absorption
of drugs by affecting various physiological processes. These
include stimulating bile ﬂow and pancreatic juice secretion57,
prolonging gastric emptying58, increasing the membrane ﬂuidity,
opening of tight junctions19,59, promoting lymphatic transport of
drugs, thus avoiding ﬁrst pass metabolism, and inhibiting efﬂux
transporters. In order to assess these effects various in vitro models
are available, including intestinal microsomes, Caco-2 cells,
everted gut sac, Using chamber, and in situ perfusion assays60.
3.3. Regulatory status of lipid excipients
Not all excipients are inert substances, and some may be toxic at
increased concentrations61. In the Code of Federal Regulations, the
FDA has published a list of substances that are generally
recognized as safe (GRAS). Apart from this, it also maintains a
list of inactive ingredients for excipients entitled Inactive Ingre-
dient Guide (IIG) that are approved and can be incorporated in
marketed products62. This guide provides the list of maximum
amount allowed for excipients, which can be used for a speciﬁc
route of administration. Once an inactive ingredient has been
approved for a product through a particular route of administra-
tion, it can be used in any new drug formulation and does not
require extensive review. The formulator can take the information
from both GRAS and IIG when developing a new formulation.
Currently, the FDA does not have any process or mechanism to
evaluate the safety of excipients individually. Instead, the exci-
pients are reviewed and approved as ‘components’ of the drug or
biological product in the application. Since excipients play an
integral part in the formulation and cannot be reviewed separately
from the drug formulation, the regulatory process is appropriate
from a scientiﬁc standpoint.4. Lipid-based formulations
4.1. Lipid formulation classiﬁcation system
A working model of a lipid formulation classiﬁcation system
(LFCS) was introduced in 200010 and an extra type of formulation
was added in 20068. The in vivo behavior of the formulation can
be interpreted easily by LFCS. With reference to the physico-
chemical properties of speciﬁc drugs, the most suitable formula-
tion can be identiﬁed through LFCS. Table 3 shows the various
classes of LFCS. Most of the marketed products are Type III
systems, which are diverse with a wide range of oil- and water-
soluble substances. Hence, this group has been further divided into
Type III A (oils) and Type III B (water-soluble) based on the
proportion of oils and water-soluble substances8,10.
Table 3 The lipid formulation classiﬁcation system14.
Type I Type II Type IIIA (ﬁne emulsion) Type IIIB (microemulsion) Type IV
Oils without
surfactants
Oils and water
insoluble
surfactants
Oils, surfactants, cosolvents
(both water-insoluble and water-
soluble excipients)
Oils, surfactants, cosolvents (both
water-insoluble and water-
soluble excipients)
Water-soluble
surfactants and cosolvents
(no oils)
Non-dispersing Emulsion (SEDDS) SEDDS/SMEDDS formed
with water-soluble components
SEDDS/SMEDDS formed with
water-soluble components and
low oil content
Disperses typically
to form a micellar
solution
Requires digestion Will be digested Digestion may not be necessary Digestion may not be necessary Limited digestion
Table 4 Commercially available Lipid-based products for oral administration41.
Trade name Molecule Therapeutic use Company
Agenerases Amprenavir HIV antiviral Glaxo SmithKline
Rocaltrols Calcitriol Calcium regulator Roche
Cipros Ciproﬂoxacin Antibiotic Bayer
Neorals Cyclosporin A/I Immuno-suppressant Novartis
Gengrafs Cyclosporin A/III Immuno-suppressant Abott
Accutanes Isotretinoin Anti-comedogenic Roche
Kaletras Lopinavir and Ritonavir HIV antiviral Abott
Norvirs Ritonavir HIV antiviral Abott
Lamprenes Clofazamine Treatment of Leprosy Alliance laboratories
Sustivas Efavirenz HIV antiviral Bristol-Meyers
Fenogals Finoﬁbrate Anti hyperlipproteinomic Genus
Restandols Testosterone undecanoate Hormone replacement therapy Organon laboratories
Convulexs Valproic acid Anti epileptic Pharmacia
Juvelas Tocopherolnicotinate Hypertension, hyperlipidemic Eisai Co.
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Lipid-based drug delivery systems can be developed successfully
by careful consideration of the formulation objectives. Table 4
indicates the list of commercially available lipid-based products41.
The systematic approach includes pre-selection of excipients based
on their melting point, fatty acid composition, HLB value,
digestibility and disposability; screening of selected excipients
for solubility, dissolution/dispersion properties, stability and com-
patibility; identiﬁcation of a formulation technique which is
suitable for the intended dosage form; design of appropriate
animal models to predict the in vivo performance of the chosen
formulation; and optimization of the formulation considering the
drug loading and dissolution proﬁle.4.2.1. Oily liquids
Some drugs are highly lipophilic and have solubility in oils only,
e.g. steroids, and are solubilized in triacyglycerols only. Such
drugs have to be formulated as oily liquids by solubilizing the drug
in oil. But the quantity of oil required to dissolve a unit dose of
drug is very high, which restricts or limits the usage of drug in oil
formulations. An oily solution of bupivacaine free base was
formulated, using a mixture of fractionated coconut oil (Visco-
leos) and castor oil by Larsen et al.63. The formulated oily liquid
showed a prolonged local analgesic activity and reduced systemic
toxicity when administered subcutaneously to male Wistar rats.4.2.2. Mixed micelles
These systems consist of more than one molecular species. These
micelles represent a disc like structure and resemble a lipid bilayer.
In detergent-lipid mixed micelles, the detergent molecules shield
the lipid molecules against water at the edges. Increased activity
against taxol-resistant and sensitive lung cancer cell lines was
observed when paclitaxel and parthenolide were co-encapsulated
in mixed micelles of PEG 2000 – distearoyl phosphatidylethano-
lamine (DSPE) and Vitamin E TPGS64. Chen et al.65 reported
enhanced anti-tumor activity of methotrexate against multidrug
resistant tumors when conjugated with polymeric mixed micelles
(composed of Pluronic F127 and P105).4.2.3. Self-emulsifying systems
As the name suggests, these systems have the ability to emulsify
due to the presence of one or more surfactants in addition to the
oily phase. The lipophilic drug is solubilized in the oily vehicle.
The surfactant helps in dispersing the oily vehicle in the GI ﬂuid,
which leads to the formation of a micro-emulsion. Depending
upon the size of the emulsion particles, these systems can be
further classiﬁed as self-micro emulsifying drug delivery systems
(SMEDDS) or self-nano emulsifying drug delivery systems
(SNEDDS). The formulation generally consists of drug, oily
vehicle, surfactant, co-surfactant and even co-solvents. Puerarin
SMEDDS sustained release pellets for oral delivery were devel-
oped using castor oil as the oil phase, Cremophors EL as the
emulsiﬁer, and 1,2-propanediol as the co-emulsiﬁer by Zhang
Lipid-based drug delivery systems 367et al.66. The formulated self-emulsifying pellets provided a
sustained drug release while simultaneously improving the oral
bioavailability of puerarin.
4.2.4. Lipososmes
Liposomes have spherical bilayer structures which resemble the
cell membrane in their arrangement. The lipids mainly used are
phospholipids, which are amphiphilic in nature, having a hydro-
philic head and hydrophobic tail (fatty acid). These phospholipids
when hydrated in water form spherical bilayer structures, orienting
with their hydrophobic part facing each other (toward inside) and
hydrophilic part facing outwards. The advantage of these systems
is that hydrophilic substances can be embedded in the aqueous
internal spaces of the globules, while hydrophobic drugs can be
embedded within the inner fatty acid layers. Propylene glycol
liposomes loaded with epirubicin have been reported to overcome
multi-drug resistance in breast cancer. These liposomes showed a
good permeability to both the cell membrane and nuclear
membrane of the tumor cell67.
4.2.5. Solid lipid nanoparticles
Recently, solid lipid nanoparticles (SLN) have gained much
interest due to their ability to enhance bioavailability along with
controlled and site-speciﬁc drug delivery. Hence they are exploited
as probable possibilities as carriers for oral intestinal lymphatic
delivery. SLNs are typically spherical particles (size range 10–
1000 nm) with a solid lipid core matrix (stabilized by surfactants)
that can solubilize lipophilic molecules. Lipids mainly used
include monoglycerides (e.g. glycerol monostearate), diglycerides
(e.g. glycerol behenate), triglycerides (e.g. tristearin), fatty acids
(e.g. stearic acid), steroids (e.g. cholesterol), and waxes (e.g. cetyl
palmitate). As reported by Venishetty et al.68, the oral bioavail-
ability of carvedilol could be improved by formulating a polymer
(N-carboxymethyl chitosan) that coated carvedilol solid lipid
nanoparticles. Monoglyceride was used as the lipid along with
soya lecithin and poloxamer 188 as surfactants for the formulation
of carvedilol-loaded SLN.
4.3. Conversion of liquid–lipid formulations to solid
intermediates
Oral delivery is the most preferred and popular route of drug
administration. Liquids and solids can be given through oral route.
With regard to the physical and chemical stability of liquids and
semisolids, these can be transformed into solid particles (powders
or granules), which can be ﬁlled into capsules or alternatively
compressed into tablets by selecting suitable tableting excipients.
4.3.1. Spray congealing
This is also referred to as spray cooling. In this method, molten
lipid is sprayed into a cooling chamber and, on contact with the
cool air, congeals into spherical solid particles. The solid particles
are collected from the bottom of the chamber, which can be ﬁlled
into hard gelatin capsules or compressed into tablets. Ultrasonic
atomizers are frequently used to generate solid particles in this
spray cooling process. The parameters to be considered are the
melting point of the excipient, the viscosity of the formulation and
the cooling air temperature inside the chamber to allow instant
solidiﬁcation of the droplets. Praziquantel granules were prepared
by melt granulation using PEG 4000 or Poloxamer 188 as a
meltable binder and lactose monohydrate as ﬁller69. In anotherstudy by Cavallari et al.70, microparticles with narrow size
distribution were obtained when stearoyl polyoxylglycerides
(Gelucires 50/13) were used as an excipient and signiﬁcantly
enhanced the drug release of poorly water soluble drugs like
diclofenac.
4.3.2. Spray drying
This method is somewhat similar to previous one, but differs in the
temperature of the air inside the atomizing chamber. In this
method, the drug solution (drug in organic solution/water) is
sprayed into a hot air chamber, where the organic solvent or water
evaporates giving rise to solid microparticles of drug. During this
process, along with the lipid excipients, solid carriers like silicon
dioxide can be used. Gelucire™ (lipid excipient), enhances the
drug release process by forming hydrogen bonds with the active
substance, leading to the formation of stable solids of amorphous
drug in microparticles71,72. Solid dispersions of glibenclamide
were prepared using a spray drying technique by Chauhan et al.72.
In this method, glibenclamide was dissolved in sufﬁcient solvent
to yield a clear solution. Silicon dioxide was added and the
resulting suspension was spray-dried using a spray dryer under
ﬁxed conditions of inlet and outlet temperature, feed rate and
atomization air pressure.
4.3.3. Adsorption onto solid carrier
This is a simple process and economical (in the context of
equipment investment). In this method, a liquid–lipid formulation
is adsorbed onto solid carrier like silicon dioxide, calcium silicate
or magnesium alumino-metasilicate. The liquid–lipid formulation
is added to the carrier by mixing in a blender. The carrier must be
selected such that it must have greater ability to adsorb the liquid
formulation and must have good ﬂow property after adsorption.
Gentamicin and erythropoetin with caprylocapryoyl polyoxylgly-
cerides (Labrasols) formulations were successfully converted into
solid intermediates whose bioavailability was maintained even
after adsorption on carriers. Advantages of this method include
good content uniformity and high lipid exposure73–75. Ito and
co-workers75 have developed a solid formulation of gentamicin
using emulsiﬁer and adsorbent. Using solid adsorbents like
calcium silicate, magnesium alumino-metasilicate and silicon
dioxide, the liquid mixture (drug and emulsiﬁer like Labrasols)
was converted to a solid by a kneading process.
4.3.4. Melt granulation
This is also referred as pelletization, which transforms a powder mix
(with drug) into granules or pellets76–78. In this method a meltable
binder (molten state) is sprayed onto the powder mix in presence of
high-shear mixing. This process can be referred to as a ‘pump on’
technique. Alternatively, the meltable binder is blended with powder
mix and due to the friction of particles (solid/semisolid) during the
high-shear mixing, the binder melts. The melted binder forms liquid
bridges between powder particles and forms small granules which
transform into spheronized pellets under controlled conditions. Depend-
ing on the ﬁneness of the powder, 15%–25% of the lipid-based binder
can be used. The parameters to be considered during the process are
binder particle size, mixing time, impellar speed and viscosity of the
binder on melting79. The dissolution rate of diazepam was improved by
formulating melt agglomerates containing solid dispersions of diaze-
pam by Seo et al.80. Lactose monohydrate was melt-agglomerated with
a meltable binder like PEG 3000 of Gelucires 50/13 in a high shear
mixer. Polyoxylglycerides, partial glycerides or polysorbates, and
S. Kalepu et al.368lecithins are some of the lipid excipients used in the melt granulation
technique to form self-micro-emulsifying systems80,81.
4.3.5. Supercritical ﬂuid-based method
This method uses lipids for coating drug particles to produce solid
dispersions. In this method, the drug and lipid-based excipients are
dissolved in an organic solvent and then in supercritical ﬂuid
(carbon dioxide)82,83, by elevating the temperature and pressure.
The coating process is facilitated by a gradual reduction in
pressure and temperature in order to reduce the solubility of the
coating material in the ﬂuid and hence precipitate onto the drug
particles to form a coating84,85. The solubility of the formulation
components in the supercritical ﬂuid and stability of the substance
during the process are important considerations of this method.
Glyceryl trimyristate (Dynasan™ 114) and steoaroyl polyoxylgly-
cerides (Gelucires 50/02) have been used in this process for their
controlled-release applications82,83. Sethia and squillante84–86 have
formulated solid dispersions of carbamazepine using supercritical
carbon dioxide. Vitamin E TPGS and Gelucires 44/14 were
successfully used with this technique (supercritical ﬂuid proces-
sing) for enhancement of the bioavailability of carbamazepine. The
solid dispersions formulated with TPGS showed enhanced bioa-
vailability of drug when compared to formulations prepared with
Gelucires 44/14 as lipid excipient.
4.4. Characterization of lipid-based formulations
4.4.1. In vitro studies
A preliminary guideline for formulation development and assess-
ment of drug release can be obtained from in vitro studies. Apart
from assessing batch-to-batch consistency, these studies also
depict the in vivo evaluation of the lipid-based formulation.
In vitro evaluation of lipid-based drug delivery systems can be
done with the use of lipid digestion models. In order to assess the
performance of an excipient during formulation development and to
predict in vivo performance, it is necessary to design an in vitro
dissolution testing method. This can be termed as “simulated lipolysis
release testing”, which is described in the literature19. The instrument
used for studying enzymatic hydrolysis of lipids is a pH-stat titration
system, which is depicted in Fig. 3. The basic principle on which this
system works requires maintaining a constant pH during a reaction
which releases or consumes hydrogen ions. If any deviation is found,
it is compensated by the reagent addition.Figure 3 pH-Stat titration system.The model consists of a temperature-controlled vessel (37 1C),
which contains a model intestinal ﬂuid, composed of digestion
buffer, bile salt (BS) and phospholipid (PL). Into this model a ﬂuid
lipid-based formulation is added and to initiate the digestion
process pancreatic lipase and co-lipase were added. As the
digestion process starts it results in the liberation of fatty acids,
causing a transient drop in pH. This drop in pH is quantiﬁed by a
pH electrode. The pH electrode is coupled to a pH-stat meter
controller and autoburette. An equimolar quantity of sodium
hydroxide is added to titrate the liberated fatty acids by the
autoburette, so as to prevent a change in pH of the digestion
medium from a pre-set pH value. By quantifying the rate of
sodium hydroxide addition and considering the stoichoimetric
relationship between fatty acids and sodium hydroxide, the extent
of digestion can be quantiﬁed. During the digestion process,
samples can be withdrawn and separated into a poorly dispersed
oil phase, highly dispersed aqueous phase and precipitated pellet
phase by centrifugation, as shown in Fig. 4. Quantiﬁcation of drug
in the highly dispersed aqueous phase indicates that drug has not
precipitated, from which an assumption can be made with respect
to in vivo performance of the lipid-based formulation.
The effect of the concentration of bile salts, calcium and lipase
activity on the digestion process was investigated87,88. Results
showed that all three parameters had an impact on the initial rate of
hydrolysis, whereas the subsequent stages were affected by
calcium concentration and lipase activity. To study effect of food
for poorly water-soluble drugs, an in vitro lipid digestion model
was developed by Christensen and co-workers89. In this model, the
transfer of lipophilic drugs from fractionated coconut oil and
sesame oil to the aqueous phase was studied. Dahan and Hoff-
man90 have presented the importance of in vitro lipolysis model
for optimizing the oral lipid-based formulations with regard to pre-
systemic metabolism in the gut.4.4.2. In vivo studies
The impact of excipients on the bioavailability and pharmacoki-
netic proﬁle of drugs can be estimated by designing appropriate
in vivo studies. A detailed study of intestinal lymphatic absorptionFigure 4 Phase separation in the lipolysis sample after ultracen-
trifugation.
Lipid-based drug delivery systems 369is required, since lipid-based formulations enhance bioavailability
by improving the intestinal uptake of drug. Due to insufﬁcient
clinical data and differences in methods and animal models used,
studies related to the drug transport by lymphatic system have
become difﬁcult91. Hence further work has to be carried out to
establish an in vivo method and model to predict lymphatic drug
transport. A lipid-based formulation of saquinavir mesylate (For-
tovases) enhanced the bioavailability of the drug up to three-fold
when compared to Invirases (saquinavir in hard gelatin cap-
sules)92. A study in a mesenteric lymph duct-cannulated rat model
was conducted to understand the mechanism for the improved
bioavailability with this formulation. The results showed that
enhanced solubilization and permeability of the drug in the
lipid-rich pre-absorptive intestinal environment was the main
reason for the increase bioavailability from Fortovases39.
In lymphatic absorption the important step is the association of
drug with chylomicrons in the enterocyte. In order to study this, an
experimental rat model with blocked chylomicron ﬂow to eluci-
date the lymphatic transport of Vitamin D3 was conducted. Upon
comparison of these results with the mesenteric lymph duct-
cannulated rat model, it showed that the association of drug with
chylomicrons led to 75% of the Vitamin D3 being absorbed
through lymphatic uptake93–95. The effect of food (high fatty meal)
on the bioavailability of cyclosporine was studied by formulating
the drug as Sandimmune Neorals (lipid-based formulation-
microemulsion of a surfactant, lipophilic and hydrophilic solvents,
and ethanol), and simple emulsion in soft gelatin capsules, and was
carried out in healthy human volunteers. The results conﬁrmed that
the effect of food was lessened with the lipid-based formulation
(Sandimmune Neorals), when compared to a signiﬁcant effect of
food (37% increase in area under the curve) from the simple
emulsion. This allowed more ﬂexibility of the lipid-based for-
mulation with regards to their dietary schedule94.4.4.3. In vitro–in vivo correlation (IVIVC)
The in vivo oral bioavailability of two model drugs, griseofulvin
and dexamethasone, was predicted by designing an in vitro
lipolysis and ex vivo intestinal permeability model. Both drugs
had good correlation with their in vitro and in vivo data in regards
to lipolysis and absorption. But, the actual in vivo data failed to
correlate with the ex vivo permeation studies. Griseofulvin, with
limited solubility (5 mg/mL), is inﬂuenced by the lipid excipients,
the presence of bile salts, phospholipids and lipolytic products in
the digestive media95. A sound in vitro–in vivo correlation will
help to maximize the development potential and commercializa-
tion of lipid-based formulations. A shortened drug development
period and improved product quality could be achieved by
developing a model that correlates the in vitro and in vivo data.
Determining the solubility, dissolution, lipolysis of the lipid
excipient, intestinal membrane techniques (isolated animal tissue
and cell culture models) are various in vitro techniques that can be
used to assess lipid-based formulations96. Such techniques provide
information about speciﬁc aspects of the formulation only. But, it
is important to know the in vivo interaction and performance of
these systems.
Similar to that of in vivo enterocytes, Caco-2 cells produce and
secrete chylomicrons on exposure to lipids. More study has to be
carried out on the choice of the most suitable in vivo model for
assessing the lipid-based formulations.
For initial screening and identifying a prototype formulation,
the rat is a reliable model. However, the different anatomy andphysiology the rat, such as the lack of a gall bladder and different
expression and pattern levels for intestinal enzymes makes
correlation of results to human beings challenging. Several lipid-
based formulations have been assessed using a dog model97, but a
poor correlation was observed between dog and human due to
differences in GIT physiology like gastric pH and enzymatic
proﬁle of enterocytes. In terms of close relation between the
anatomy and physiology of the GIT, the pig can be considered as a
most suitable non-primate animal model98. This model permits the
oral administration of full-sized human dose, and even fed versus
fasting studies can be done. The impact of intestinal absorption
and ﬁrst-pass metabolism of drugs can be studied using the pig
model99. Hence, in order to establish reliable in vitro–in vivo
correlations in lipid-based formulations, selection of the most
appropriate in vitro and in vivo models is of primary importance.5. Conclusions
As many drugs are successfully marketed as lipid-based formula-
tions, the lipid-based drug delivery system (LBDDS) has a wide
scope in terms of solubility and bioavailability enhancement. This
review focused on the current trends in the ﬁeld of LBDDS with
respect to formulation approaches and their characterization.
However, a few limitations of the technology such as the stability
of lipid-based formulations, manufacturing methods, the lack of a
database considering the solubility of drugs in lipids, indicate that
development of proper regulatory guidelines for lipid-based
formulations still need to be addressed in depth to advance the
technology. Further research has to be carried out in this ﬁeld
regarding the design of a proper in vivo model to correlate the data
obtained in vitro studies to the actual in vivo experience. This
review provides a summary of lipid-based formulations which may
be helpful for the advancement of this technology to obtain a safer,
more stable and efﬁcacious drug products.References
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